Daiwa Securities Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$24.1M Buy
38,643
+2,118
+6% +$1.44M 0.05% 217
2026
Q1
$28.2M Buy
36,525
+6,754
+23% +$5.17M 0.08% 138
2025
Q4
$23M Sell
29,771
-2,058
-6% -$1.4M 0.07% 165
2025
Q3
$17.9M Buy
31,829
+7,500
+31% +$4.24M 0.06% 187
2025
Q2
$12.8M Buy
24,329
+761
+3% +$425K 0.05% 235
2025
Q1
$14.9M Buy
23,568
+1,906
+9% +$1.31M 0.06% 189
2024
Q4
$15.4M Buy
21,662
+1,278
+6% +$1.07M 0.07% 169
2024
Q3
$21.4M Buy
20,384
+2,234
+12% +$2.49M 0.1% 127
2024
Q2
$19.1M Buy
18,150
+949
+6% +$920K 0.1% 123
2024
Q1
$16.6M Buy
17,201
+2,115
+14% +$2.01M 0.09% 127
2023
Q4
$13.3M Buy
15,086
+878
+6% +$723K 0.08% 140
2023
Q3
$11.9M Buy
14,208
+1,528
+12% +$1.2M 0.08% 140
2023
Q2
$9.11M Buy
12,680
+21
+0.2% +$16.2K 0.06% 175
2023
Q1
$10.4M Buy
12,659
+634
+5% +$478K 0.07% 157
2022
Q4
$8.68M Buy
12,025
+359
+3% +$265K 0.07% 179
2022
Q3
$8.04M Buy
11,666
+667
+6% +$420K 0.07% 173
2022
Q2
$6.72M Buy
10,999
+631
+6% +$410K 0.05% 205
2022
Q1
$7.58M Buy
10,368
+939
+10% +$594K 0.05% 208
2021
Q4
$6.42M Buy
9,429
+226
+2% +$139K 0.04% 246
2021
Q3
$6.2M Buy
9,203
+1,323
+17% +$821K 0.04% 220
2021
Q2
$4.4M Buy
7,880
+238
+3% +$121K 0.03% 267
2021
Q1
$3.62M Buy
7,642
+826
+12% +$402K 0.03% 284
2020
Q4
$3.29M Buy
6,816
+359
+6% +$194K 0.03% 279
2020
Q3
$3.61M Sell
6,457
-999
-13% -$606K 0.03% 221
2020
Q2
$2.16M Hold
7,456
0.05% 217
2020
Q1
$3.64M Sell
7,456
-1,507
-17% -$622K 0.04% 207
2019
Q4
$3.37M Sell
8,963
-135
-1% -$45.4K 0.03% 254
2019
Q3
$2.52M Buy
9,098
+1,881
+26% +$557K 0.02% 300
2019
Q2
$2.26M Buy
7,217
+222
+3% +$73.9K 0.02% 306
2019
Q1
$2.87M Sell
6,995
-2,373
-25% -$977K 0.03% 264
2018
Q4
$4.32M Sell
9,368
-2,490
-21% -$911K 0.04% 203
2018
Q3
$4.79M Sell
11,858
-2,070
-15% -$788K 0.04% 226
2018
Q2
$5.05M Buy
13,928
+1,075
+8% +$336K 0.04% 230
2018
Q1
$4.63M Buy
12,853
+9,433
+276% +$3.28M 0.04% 239
2017
Q4
$1.29M Sell
3,420
-11,942
-78% -$4.84M 0.01% 452
2017
Q3
$6.87M Sell
15,362
-1,295
-8% -$616K 0.05% 177
2017
Q2
$8.18M Sell
16,657
-1,002
-6% -$438K 0.05% 142
2017
Q1
$6.84M Buy
17,659
+11,486
+186% +$4.26M 0.04% 171
2016
Q4
$2.27M Sell
6,173
-3,910
-39% -$1.49M 0.01% 261
2016
Q3
$4.05M Buy
10,083
+2,183
+28% +$876K 0.02% 190
2016
Q2
$2.76M Sell
7,900
-7,975
-50% -$3.07M 0.02% 246
2016
Q1
$5.72M Buy
15,875
+2,320
+17% +$956K 0.04% 157
2015
Q4
$7.36M Sell
13,555
-5,675
-30% -$3.07M 0.05% 127
2015
Q3
$8.94M Sell
19,230
-640
-3% -$344K 0.06% 116
2015
Q2
$10.1M Buy
19,870
+2,440
+14% +$1.19M 0.07% 122
2015
Q1
$7.87M Buy
17,430
+3,630
+26% +$1.54M 0.05% 126
2014
Q4
$5.66M Buy
13,800
+10,630
+335% +$4.18M 0.04% 139
2014
Q3
$1.14M Buy
3,170
+1,070
+51% +$359K 0.01% 278
2014
Q2
$593K Sell
2,100
-100
-5% -$29.6K ﹤0.01% 369
2014
Q1
$661K Hold
2,200
0.01% 346
2013
Q4
$606K Hold
2,200
0.01% 352
2013
Q3
$688K Hold
2,200
0.01% 328
2013
Q2
$495K Buy
+2,200
New +$512K ﹤0.01% 417

Other funds holding REGN

Daiwa Securities Group's REGN Position: Q2 2026 in Review

Daiwa Securities Group increased its Regeneron Pharmaceuticals (REGN) stake by 5.8% in Q2 2026, buying an estimated $1.44M and bringing the position to 38,643 shares worth $24.1M. The position accounts for 0.05% of the portfolio, ranked #217.

Daiwa Securities Group first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $28.2M in Q1 2026. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Daiwa Securities Group held 38,643 shares of Regeneron Pharmaceuticals worth $24.1M as of Q2 2026.
  • Daiwa Securities Group bought 2,118 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
  • Regeneron Pharmaceuticals made up 0.05% of Daiwa Securities Group's portfolio in Q2 2026, its #217 holding.
  • Daiwa Securities Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Daiwa Securities Group's Regeneron Pharmaceuticals position peaked at $28.2M in Q1 2026.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Daiwa Securities Group's 13F filing for Q2 2026, filed 31 Jul 2026.